Tesamorelin and Visceral Fat: The One GH Peptide With FDA Approval

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog and the one growth-hormone peptide that is genuinely FDA-approved, sold as Egrifta, Egrifta SV, and the weekly Egrifta WR. Its approval is narrow and specific: reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy who are on antiretroviral therapy. In that population, randomized trials show a roughly 15 to 18 percent mean reduction in visceral fat versus placebo. Outside that indication, use for general fat loss or anti-aging is off-label and far less supported, and it remains prescription-only and banned in sport.

What tesamorelin is

Tesamorelin is a synthetic version of GHRH (specifically GHRH 1-44) with a chemical modification on its N-terminus that resists breakdown by the DPP-IV enzyme, giving it a usable duration in the body. Like other GHRH analogs, it does not supply growth hormone directly. Instead it binds GHRH receptors on the pituitary gland and prompts the gland to release more of its own GH in pulses, which then raises insulin-like growth factor 1 (IGF-1) and, through that, influences fat metabolism.

The brand history matters because it signals legitimacy. Egrifta was first approved in November 2010, a reformulated Egrifta SV followed in 2019, and a long-acting weekly formulation, Egrifta WR, was approved in March 2025, cutting dosing from daily to weekly. These are FDA-reviewed prescription products, not gray-market vials.

Why visceral fat is the target

Visceral adipose tissue (VAT) is the metabolically active fat packed around the abdominal organs, distinct from the subcutaneous fat just under the skin. In HIV-associated lipodystrophy, antiretroviral therapy and the disease itself can drive a buildup of this visceral fat, which is associated with metabolic and cardiovascular problems. Tesamorelin's GH-mediated effect on fat metabolism happens to act preferentially on that visceral depot, which is precisely why it was developed and approved for this condition.

That mechanism is also why off-label interest exists. People who want to lose stubborn abdominal fat hear "reduces visceral fat" and assume it will work for them. The catch is that the trials were run in a specific population with a specific condition, and the result does not automatically generalize. If you want to understand fat-loss peptides more broadly, our guide to the best peptides for fat loss puts tesamorelin in context.

It also helps to be precise about what tesamorelin does not do. It is not a general weight-loss drug, and it was not approved as one. In its trials it preferentially reduced the visceral depot while having far less effect on subcutaneous fat or total body weight, which is the opposite of what most people picture when they imagine a fat-loss compound. The benefit, where it exists, is specifically about the metabolically harmful fat around the organs, not about the number on the scale or the fat you can pinch. And because the effect depends on ongoing GH-axis stimulation, visceral fat tends to return after the drug is stopped, so it is not a one-time correction.

The evidence: strong for one use, thin for the rest

This is the cleanest evidence story in the growth-hormone peptide world, and it is worth being precise about.

For the approved indication, the data is solid. Large, published, placebo-controlled randomized trials in people with HIV-associated lipodystrophy showed a roughly 15 to 18 percent mean reduction in visceral fat versus placebo. That is real, replicated, regulator-reviewed evidence, the kind that almost no other peptide in this category can claim.

For off-label use in otherwise healthy people seeking body recomposition or anti-aging, there is no equivalent randomized-trial evidence. The case rests on extrapolation from the HIV data plus the general class effects of GH secretagogues. Extrapolation is not proof, and the populations differ in ways that matter, so the honest framing is that off-label efficacy and safety are not established. We dig into that gap in GH peptides for body recomposition.

Why does the extrapolation deserve skepticism rather than a shrug? People with HIV-associated lipodystrophy have an abnormal, disease-driven pattern of visceral fat accumulation, and tesamorelin was tested as a correction for that specific abnormality. A healthy person with ordinary abdominal fat is not in the same physiological situation, so there is no guarantee the same magnitude of effect, or any meaningful effect, carries over. This is a recurring trap with repurposed drugs: a strong result in one population gets quietly rebranded as a general benefit, and the evidence does not actually support the rebrand.

How tesamorelin compares to other GHRH peptides

Peptide	FDA approval	Evidence quality	Half-life and dosing	Status outside approval
Tesamorelin (Egrifta)	Approved for HIV lipodystrophy	Strong RCT data in indication	Daily, or weekly with Egrifta WR	Off-label use not approved; WADA-banned
CJC-1295 (with DAC)	Not approved	Limited early-phase human data	Long, roughly 6 to 8 days	Research chemical; WADA-banned
Sermorelin	Not currently approved (prior approval withdrawn)	Limited human data; older clinical history	Short, roughly 10 to 20 minutes	Compounded off-label; WADA-banned

This table compares approval status and evidence, not doses. Tesamorelin's dose in its approved use is set in the prescribing information and titrated by a clinician, never self-selected.

Regulatory status: prescription-only, and the one that is approved

Tesamorelin is a prescription drug. It is not a controlled substance, but it cannot be obtained legally without a prescription from a licensed provider. Off-label prescribing for uses beyond HIV lipodystrophy is legal in the US, but it shifts responsibility, documentation, and informed consent onto the prescriber, and it does not make those uses FDA-approved.

For athletes, note that tesamorelin is on the WADA Prohibited List under category S2 as a GHRH analog, banned at all times. Being FDA-approved for a medical condition does not exempt it from anti-doping rules.

The contrast with the rest of its class is the whole point. Where CJC-1295, ipamorelin, and most peptides circulate as unregulated research chemicals, tesamorelin moves through the legitimate prescription pathway with a real label and real monitoring requirements. Our overview of how growth-hormone peptides work explains where each one sits.

Common reported uses and the off-label line

Beyond its approved indication, tesamorelin draws off-label interest for general abdominal fat reduction, body recomposition, and anti-aging "GH optimization." It is important to restate plainly: these uses are not FDA-approved, the HIV-trial evidence does not automatically apply to them, and approval for one indication is not a general endorsement for fat loss. Anyone considering an off-label course is, in evidence terms, ahead of the data.

How it differs from a GLP-1 for fat

Because GLP-1 medications like semaglutide and tirzepatide dominate the fat-loss conversation, it is worth drawing the contrast plainly, since the two are not interchangeable. GLP-1 drugs reduce overall body weight largely by curbing appetite and food intake, and they reduce fat broadly across the body, including the visceral depot, as part of general weight loss. Tesamorelin does not work by suppressing appetite at all; it works through the GH axis and acts preferentially on visceral fat without producing large overall weight loss.

That difference matters for expectations. A GLP-1 user often watches the scale drop substantially, while a tesamorelin user in the approved setting might see relatively little scale change despite a meaningful reduction in the harmful visceral fat specifically. The two also carry very different evidence weights and approval scopes, and combining them is a clinical decision, not a do-it-yourself stack. Our guide to TRT and GLP-1 together covers the broader principle that body-composition agents interact in ways worth tracking.

Safety and what to monitor

Even in its approved use, tesamorelin has a real side-effect profile tied to GH-axis stimulation. The prescribing information and trials describe fluid retention and peripheral edema, joint pain, carpal-tunnel-like symptoms, and glucose intolerance, the last of which matters for anyone with diabetes or prediabetes. Because it raises IGF-1, the label directs clinicians to monitor IGF-1 levels and to discontinue if IGF-1 climbs too high for the patient's age.

It is contraindicated in people with active malignancy, in those with a pituitary tumor, and during pregnancy, reflecting the theoretical concern that raising IGF-1 could stimulate tumor growth. These are not abstract cautions; they are the reasons this drug requires a prescriber who reviews your history and labs.

The contrast with gray-market peptides is instructive here. With a prescribed, FDA-reviewed product, you get a known molecule, a manufactured product of verified quality, a label that specifies monitoring, and a clinician accountable for catching problems like a runaway IGF-1 level. A research-chemical peptide bought online offers none of that, which is one reason tesamorelin's approved pathway is genuinely safer than the alternatives, even before you get to the question of whether it works for your goal.

What to ask a provider

Useful questions for a clinician include: Does the approved HIV-lipodystrophy indication apply to me, or would this be off-label? How will we monitor IGF-1 and fasting glucose? Do I have any malignancy or pituitary history that rules it out? And does my actual goal have evidence behind it for this drug, or am I extrapolating? A provider experienced in endocrine or metabolic care can weigh these honestly.

The tracking angle

For a prescribed tesamorelin course, the question that actually matters is whether your visceral fat is moving, and the scale alone cannot tell you that. Myo logs each injection and trends visceral-versus-overall body composition alongside any GLP-1 or training data, so a fat-loss change is measured rather than assumed. That is the same fat-versus-muscle discipline we apply to telling fat loss from muscle loss on a GLP-1.

If your provider has you self-injecting, Myo handles dose logging, site rotation, and reminders, and trends IGF-1 and other labs your prescriber will want to review at follow-up. It does not replace clinical supervision; it gives you and your clinician cleaner data to act on.

References

• US FDA. Egrifta (tesamorelin) prescribing information, approved indication for HIV-associated lipodystrophy. FDA.gov.
• Theratechnologies. FDA approval of weekly Egrifta WR formulation, 2025.
• Published randomized controlled trials of tesamorelin in HIV-associated lipodystrophy reporting roughly 15 to 18 percent visceral adipose tissue reduction versus placebo.
• World Anti-Doping Agency. 2026 Prohibited List, category S2 (GHRH analogs). wada-ama.org.